Curis

Curis Current Assets

The Current Assets of Curis (CRIS) as of Nov 21, 2026 is 6.92 M USD.

Current Assets

6.92 MUSD

Last updated:

Current Assets of Curis is 2025 6.92 M USD. Current Assets of Curis was 2024 - USD. It decreases by % lower compared to the previous year.

The Curis Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 1996
53.10 M USD
Jan 1, 1997
36.70 M USD
Jan 1, 1998
58.90 M USD
Jan 1, 2004
51.51 M USD
Jan 1, 2008
29.33 M USD
Jan 1, 2010
41.09 M USD
Jan 1, 2013
70.42 M USD
Jan 1, 2025
6.92 M USD
The Curis Current Assets history
YEARCurrent AssetsYoY
6.92 MUSD-90.18%
70.42 MUSD+71.37%
41.09 MUSD+40.12%
29.33 MUSD-43.07%
51.51 MUSD-12.55%
58.90 MUSD+60.49%
36.70 MUSD-30.89%
53.10 MUSD+125.96%
23.50 MUSD+69.06%
13.90 MUSD+78.21%
7.80 MUSD-70.90%
26.80 MUSD+267.12%
7.30 MUSD+630.00%
1,000,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curis Stock analysis

What does Curis do? Curis Inc generates revenue primarily through the development and potential commercialization of its therapeutic drug candidates in the biotechnology sector. The company focuses on oncology treatments, with its lead candidate Emavusertib targeting IRAK4 kinase inhibition for cancer therapy. Other key products include Erivedge, which inhibits the Hedgehog signaling pathway, and additional candidates like CI-8993, Fimepinostat, CA-170, and CA-327, targeting various cancer-related pathways. The firm conducts R&D internally and via strategic collaborations, aiming to advance these drug candidates toward clinical and commercial stages. Curis Inc's primary buyers are pharmaceutical companies and healthcare institutions seeking innovative cancer treatments. The company's pipeline includes orally available small molecule drugs and monoclonal antibodies designed for targeted cancer therapies. Emavusertib, Erivedge, and CA-170 represent the core product segments, with CA-170 specifically targeting VISTA and PDL1 immune checkpoint proteins. Strategic collaborations support the development of these therapeutics, aligning with the company's focus on oncology drug discovery and development. The company's revenue streams are tied to the progression of its drug candidates through clinical trials and potential partnerships. Emavusertib and Erivedge are in clinical stages, with CA-170 also advancing in development. Curis Inc's business model emphasizes internal R&D alongside strategic alliances to accelerate the development of its pipeline, ensuring that its products reach the market for cancer treatment applications. Curis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curis stock

Current Assets of Curis is 6.92 M USD in 2025.

On Eulerpool you can find the complete historical development of Current Assets Curis since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Curis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Curis

All Key Metrics — Curis